GET DAILY SIGNALSTELA Bio (TELA) Q3 2026 Earnings: Cost Cuts Narrow Adjusted Loss Despite Revenue Decline
Key Takeaways
- TELA Bio reported a third-quarter 2026 adjusted (non-GAAP) net loss of $0.13 per share, beating the analyst consensus of roughly a $0.16 per share loss.
- Revenue of $18.96 million came in below the approximately $20 million consensus and declined about 8% year over year from $20.69 million.
- A cost-reduction program targeting $17 million in annualized savings, including a roughly 20% workforce reduction, helped narrow the adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss to $3.4 million.
- On a GAAP (generally accepted accounting principles) basis, the net loss widened to $9.3 million, reflecting severance and legal costs plus higher interest expense.
- Cash and cash equivalents fell to $22.7 million, and lender Perceptive agreed to suspend minimum revenue covenant testing for the third and fourth quarters.
- OviTex PRS revenue dropped 20% year over year, while Europe grew 18% and LiquiFix posted a record quarter.
Why This Quarter Matters for TELA Bio
TELA Bio's third-quarter 2026 report matters because it tests whether a new leadership team can stabilize a business that has been losing momentum. Under Chief Executive Officer Heather Getz, the company has pivoted from growth-at-any-cost toward cost discipline and a narrower operating focus. Investors are watching whether expense cuts can meaningfully reduce cash burn without further eroding the top line. With revenue growth decelerating across 2026, an earlier full-year growth outlook was withdrawn, making this quarter a key checkpoint on the path toward profitability and a longer cash runway. I also checked this using Tickeron’s AI Screener to see how TELA compares to others in the industry.
Breaking Down the Reported Results
TELA Bio reported third-quarter 2026 revenue of $18.96 million, down roughly 8% from $20.69 million in the same period a year earlier and below the consensus estimate of about $20 million. U.S. revenue was $15.4 million, while European revenue was $3.6 million.
The company posted an adjusted (non-GAAP) net loss of $0.13 per share, narrower than the roughly $0.16 loss analysts had expected. On a GAAP basis, however, the net loss widened to $9.3 million from $8.6 million a year earlier, pressured by about $2.0 million in severance and legal costs tied to restructuring and higher interest expense.
GAAP gross margin slipped to 64.9% from 67.5% due to an inventory write-off, though adjusted gross margin was roughly 71%. Operating expenses, excluding other items, fell about 17.8% year over year to $17.6 million, driving the adjusted EBITDA loss down to $3.4 million, a 40% year-over-year and 56% sequential improvement. The company ended the quarter with $22.7 million in cash and cash equivalents.
Market Reaction and Investor Sentiment
TELA shares traded around $0.80 heading into and immediately after the report, and the stock rose modestly in after-hours trading following the narrower-than-expected adjusted loss. The market's response reflected a nuanced view: investors welcomed the faster-than-expected progress on cost reduction, but the continued revenue decline and shrinking cash balance tempered enthusiasm. Sentiment remains cautious, with the stock down materially over the trailing twelve months as the company works through a go-to-market reset.
Forward Outlook and Key Factors to Monitor
Investors should watch whether the cost-reduction plan translates into a sustainable path toward breakeven without further revenue erosion. Management has framed the recovery as a multi-quarter effort, and the next few quarters will reveal whether U.S. hernia volumes can keep growing sequentially while the OviTex PRS franchise stabilizes.
Balance-sheet dynamics will also be critical. Cash declined to $22.7 million, and the $56.3 million Perceptive loan is now classified as a current liability. The suspension of minimum revenue covenant testing through the end of 2026 relieves near-term pressure but underscores financial strain. How the company manages liquidity and any potential refinancing will be closely scrutinized.
Finally, product catalysts remain on the horizon. The expected 510(k) clearance of the Liora monofilament scaffold, the company's first in-house implant, and a planned commercial launch in early 2027 could provide a fresh growth avenue. A national contracting agreement and continued European momentum are additional factors that could shape the trajectory of TELA Bio's quarterly earnings in the coming periods.
Integrating AI Tools Into My Research Process
In preparing for earnings reviews like this one, I frequently use Tickeron’s AI Screener to scan for comparable names and technical setups across the sector. It helps surface relevant data points quickly without replacing core fundamental work. The tool’s customizable filters have become a regular part of how I cross-check results against broader market signals before forming a view on names such as TELA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TELA in upward trend: price may jump up because it broke its lower Bollinger Band on October 30, 2026
TELA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 44 cases where TELA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TELA's RSI Indicator exited the oversold zone, 26 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 67 cases where TELA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +10.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TELA advanced for three days, in 182 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TELA as a result. In 89 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
TELA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TELA crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TELA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for TELA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.333) is normal, around the industry mean (4.142). P/E Ratio (-1.065) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.782) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TELA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TELA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How do various investing styles impact the process of building a portfolio?
What Were the Student Loan Debt Statistics in 2022, and What Does the Outlook Hold?
What sets Short Selling apart from Put Options?
What is the Coefficient of Variation (CV) and What Does It Tell Us About Data Dispersion?
The Powerhouses of Industrial Conglomerates: A Deep Dive into Top Stocks
General Information
a commercial stage medical technology company, which focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.
Industry MedicalNursingServices
Advertisement